<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01718639</url>
  </required_header>
  <id_info>
    <org_study_id>INQ/012512</org_study_id>
    <nct_id>NCT01718639</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn</brief_title>
  <official_title>Randomized, Controlled, Single-blind, Three-way Crossover Clinical Investigation to Evaluate Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InQpharm Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InQpharm Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, placebo-controlled, single-blind, three-way crossover clinical
      trial to evaluate safety and efficacy of IQP-LH-101 (tablet form and liquid form) in
      postprandial heartburn.

      The null hypothesis is that there is no difference between IQP-LH-101 and the placebo in
      terms of efficacy for postprandial heartburn treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in time to both onset of soothing and onset of cooling after intake of investigational product between study arms</measure>
    <time_frame>Measured up to 30 minutes</time_frame>
    <description>The subject will be provided with a stopwatch started by the study staff at the time of investigational product application</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of time until the first perception of recurring heartburn symptoms after intake of investigational product</measure>
    <time_frame>Up to 4 hours</time_frame>
    <description>The subject will be instructed to stop the stopwatch provided at first perception of recurring heartburn symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of efficacy</measure>
    <time_frame>Up to 4 hours per crossover</time_frame>
    <description>The subjects evaluate the efficacy of the device under investigation (global scaled eval-uation with &quot;very good&quot;, &quot;good&quot;, &quot;moderate&quot; and &quot;poor&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>The investigator will assess and document in the CRF any adverse events, device effects and device deficiencies.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Postprandial Heartburn</condition>
  <arm_group>
    <arm_group_label>IQP-LH-101 tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 chewable tablets to be chewed thoroughly before swallowing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IQP-LH-101 liquid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 liquid sachets to be emptied into the mouth and consumed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 tablet to be swallowed with water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IQP-LH-101 tablet</intervention_name>
    <description>Oral medical device in the form of a chewable tablet</description>
    <arm_group_label>IQP-LH-101 tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IQP-LH-101 liquid</intervention_name>
    <description>Oral medical device in the form of a liquid</description>
    <arm_group_label>IQP-LH-101 liquid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post-prandial heartburn (e.g. after a high-fat meal) in at least 2 months prior to the
             study (at least 2 times a week)

          -  Not receiving prescribed treatment for heartburn, reflux or upper gastrointestinal
             disorders

          -  Written informed consent is a prerequisite for subject enrollment.

        Exclusion Criteria:

          -  Gastrointestinal bleeding within 12 months prior to the study

          -  Difficulty swallowing (dysphagia)

          -  History of or symptoms suggestive of Zollinger-Ellison syndrome, oesophageal or
             gastric malignancy, gastric or duodenal ulcer, pernicious anaemia, Barrett's
             oesophagus or systemic sclerosis

          -  Participation in other studies within the last 30 days prior to entry or during the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Wei√üenseerweg 111</name>
      <address>
        <city>Berlin</city>
        <zip>10369</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2012</study_first_submitted>
  <study_first_submitted_qc>October 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2012</study_first_posted>
  <last_update_submitted>March 7, 2013</last_update_submitted>
  <last_update_submitted_qc>March 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heartburn</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

